LitAlert ~~ GeneLit.com

    • The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
    • Francis KE, Kim SI, Friedlander M, Gebski V, Coquard IR, Clamp A, Penson RT, Oza A, Perri T, Huzarski T, Martin-Lorente C, Cecere SC, Colombo N, Ataseven B, Fujiwara K, Sonke G, Vergote I, Pujade-Lauraine E, Kim JW, Lee CK.
    • Ann Oncol. 2022 Feb 24:S0923-7534(22)00338-6. doi: 10.1016/j.annonc.2022.02.222. Epub ahead of print.
    • Inibidores da PARP: do mecanismo de ação à prática clínica [PARP Inhibitors: From the Mechanism of Action to Clinical Practice].
    • Branco C, Paredes J.
    • Acta Med Port. 2022 Feb 1;35(2):135-143. Portuguese. doi: 10.20344/amp.13870. Epub 2022 Feb 1.